Partner Nathan Bear Appointed to Market Advisory Council by the CII for Second Consecutive Year
On January 28, 2021, the Council of Institutional Investors (CII) reappointed Robbins Geller partner Nathan Bear as a member of its Market Advisory Council (MAC). The MAC advises the board of directors and staff on legal, financial reporting, investments, and other trends.
According to the publication, “The primary purpose of [MAC] is to provide input on legal, financial reporting and investment market trends, suggest topics/speakers for upcoming CII meetings and teleconferences, and recommend current and future CII activities that promote and enhance the value of CII membership.”
When asked about his reappointment, Nate said, “I am honored to be reappointed to this incredible team and look forward to our continued efforts advocating for investors.”
Nate is a partner in the Firm’s San Diego office where he has been part of litigation teams that have recovered over $1 billion for investors, including cases In re Cardinal Health, Inc. Sec. Litig. ($600 million) and Jones v. Pfizer Inc. ($400 million). In addition to securities fraud class actions in the United States, Nate has also served as lead counsel in Villella v. Chemical and Mining Company of Chile Inc., a securities class action case against Chilean mining company SQM that resulted in a $62.5 million settlement (preliminarily approved). Nate possesses direct experience in Australian class actions, potential group actions in the United Kingdom, settlements in the European Union, the Dutch Collective Mass Claims Settlement Act, and representative actions in Germany utilizing the Capital Market Investors’ Model Proceeding Act.
Read More Firm News
- Robbins Geller Partners Aelish Baig and Jessica Shinnefield Recognized as “Born Leaders” and Plaintiffs’ Lawyers Trailblazers by The National Law JournalMay 4, 2021
- Robbins Geller Secures Appellate Win After Supreme Court of New York Appellate Division Affirms Denial of Motion to Dismiss in Securities Class Action Against Alnylam Pharmaceuticals, Inc.April 30, 2021
- April 29, 2021
- April 22, 2021
- April 21, 2021